Aytu Biopharma Unveils Strategic Focus on CNS Therapeutics and EXXUA Launch in Latest Corporate Presentation
Aytu Biopharma Inc. has released a corporate presentation detailing its strategic focus on CNS therapeutics and the launch of EXXUA in the U.S. The company reported a $34.7 million adjusted EBITDA improvement over four years, completed the wind-down of its consumer health segment, refinanced its term loan, and transitioned to a U.S.-based third-party contract manufacturer. The presentation highlights the company's prescription portfolio targeting CNS conditions and its commercial infrastructure, including the Aytu RxConnect Patient Access Program.
Aytu Biopharma Inc. has released a corporate presentation outlining its recent strategic realignment and operational developments. The company reported a $34.7 million adjusted EBITDA improvement over a four-year period, reflecting a focus on its prescription pharmaceutical business. Key recent events include the completion of the wind-down and divestiture of its consumer health segment, refinancing of its term loan, and the transition to a U.S.-based third-party contract manufacturer. In June 2025, Aytu Biopharma entered into an exclusive agreement to commercialize EXXUA™ in the United States. The presentation also details the company’s prescription portfolio, primarily targeting central nervous system (CNS) conditions, and highlights its commercial infrastructure, which includes a direct sales force covering a significant portion of the major depressive disorder and ADHD markets. The Aytu RxConnect Patient Access Program is featured as a platform developed to enhance patient access, affordability, and adherence to Aytu’s medications. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
